Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

MICHAEL E STEUER, MD, PC

NPI: 1861824559 · CORDOVA, TN 38018 · Specialist · NPI assigned 08/05/2013

$2.63M
Total Medicaid Paid
143,521
Total Claims
109,221
Beneficiaries
34
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialSTEUER, MICHAEL (MD/OWNER/PRESIDENT)
NPI Enumeration Date08/05/2013

Related Entities

Other providers sharing the same authorized official: STEUER, MICHAEL

ProviderCityStateTotal Paid
MIDSOUTH INTERVENTIONAL PAIN INSTITUTE, LLC GERMANTOWN TN $2.08M
MICHAEL E STEUER MD PC JACKSON TN $1.02M
MIDSOUTH INTERVENTIONAL PAIN INSTITUTE, LLC SOUTHAVEN MS $742K
MICHAEL E STEUER MD PC SOUTHAVEN MS $637K
MICHAEL E STEUER MD PC TUPELO MS $266K
MIDSOUTH INTERVENTIONAL PAIN INSTITUTE, LLC JACKSON TN $252K
MICHAEL E. STEUER MD PC OXFORD MS $234K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 13,373 $234K
2019 27,208 $484K
2020 25,739 $556K
2021 23,724 $488K
2022 16,324 $266K
2023 21,424 $352K
2024 15,729 $251K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 34,887 29,216 $603K
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 20,978 16,263 $490K
64483 4,523 3,928 $188K
64493 6,634 4,134 $161K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 21,898 16,081 $161K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 2,939 2,269 $150K
27096 1,793 1,636 $137K
64635 1,119 845 $96K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 10,988 8,330 $82K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 4,262 2,868 $77K
64494 6,589 4,108 $65K
99152 6,089 4,468 $65K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 3,571 2,860 $58K
64636 1,675 842 $56K
64484 3,387 2,906 $44K
64495 4,637 2,826 $42K
64454 879 743 $38K
99203 Office or other outpatient visit for the evaluation and management of a new patient, low complexity 1,133 826 $33K
64479 393 316 $18K
64418 553 464 $17K
64490 445 258 $12K
64450 303 278 $9K
L0650 Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf 21 12 $6K
77002 1,015 775 $5K
64491 387 227 $4K
20610 188 128 $4K
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) 1,259 917 $2K
64492 206 122 $2K
64480 105 88 $1K
64999 25 15 $1K
99153 Mod sedat endo service >5yrs 534 392 $1K
64625 20 13 $665.84
20611 13 13 $482.21
80305 73 54 $56.31